LongeVC is a venture capital firm that invests in early-stage biotechnology and longevity companies, focusing on innovations that extend healthspan and address age-related diseases. Their strategy targets three main pillars: therapeutics, early-stage diagnostics and personalized care, and longevity infrastructure, prioritizing science-driven ventures with strong translational potential.
67% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Their most common stage is series-a (67% of deals). Average disclosed round size is $28.6M (across 5 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Valink Therapeutics | Series A | $11.8M | Oct 2025 |
 Trogenix | Series A | $80M | Oct 2025 |
 Unnatural Products, Inc. | Series A | $32M | Dec 2023 |
| HHaut.AI | Seed | $2M | Nov 2023 |
 Turn Biotechnologies | Unknown | — | Apr 2022 |
 SiPhox Health | Series A | $17M | — |
Top Co-Investors
Astellas Venture Management1 shared
IQ Capital1 shared
4BIO Capital1 shared
Cancer Research Horizons1 shared
Brain Tumor Investment Fund1 shared
Eli Lilly and Company1 shared
Calculus Capital1 shared
Khosla Ventures1 shared
Intel Capital1 shared
Alumni Ventures Group1 shared
MetaPlanet1 shared
Shorewind Capital1 shared
Overlap Holdings1 shared
Duke Capital Partners1 shared
Human Ventures1 shared
Merck Global Health Innovation Fund1 shared
Spark Capital1 shared
The Venture Collective1 shared
Humain1 shared
Not Boring Capital1 shared
Last updated: 16 April 2026